Dipeptidyl peptidase‐4 inhibitor and insulin combination treatment in type 2 diabetes and chronic kidney disease: A meta‐analysis

AIMS/INTRODUCTION: The union of dipeptidyl peptidase‐4 inhibitors and insulin in patients with type 2 diabetes and chronic kidney disease provides satisfactory glucose management without increasing adverse events (AEs). This research appraised the therapeutic effect and safety of combination therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xianling, Shi, Heng, Zhu, Shiping, Wang, Haixia, Sun, Shengyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902402/
https://www.ncbi.nlm.nih.gov/pubmed/34551206
http://dx.doi.org/10.1111/jdi.13675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902402/
https://www.ncbi.nlm.nih.gov/pubmed/34551206
http://dx.doi.org/10.1111/jdi.13675

Ejemplares similares